Dosage and administration
DOSAGE: USUAL DOSE; 4-1/2 minimis 3 times daily. Dilute with water or juie. USUSAL DOSE RANGE: 1-1/2 to 15 minims daily.
DOSAGE: USUAL DOSE; 4-1/2 minimis 3 times daily. Dilute with water or juie. USUSAL DOSE RANGE: 1-1/2 to 15 minims daily.
Strong Iodine Solution
Iodine 5 %
Potassium iodide 10%
Iodine supplement
Read the following indications, Side Effects, Precautions and Caotraindications as a reminder in evaluating each case for supplemental iodine.
Source of Iodne
INDICTAIONS: This product has several uses where iodine is indicated. This product may be used in the treatment of hyperthyroidism in the immediate preoperative period in preparation for thyroidectomy. It may be used alone, but more frequently is used after the hyperthyroidism is controlled by an antithyroid drug. It is given during the 10 days immediately prior to the operation. Optimal control of Hyperthyroidism is achieved if antithyroid drugs are first given alone. This product is also used in thyrotoxicosis crisis in conjunction with supportive measures to control fever and adequate fluid intake.
Iodine should not be given to cases of active Tuberculosis, or those known to be sensitive to iodine, and discontinued in cases later developing a sensitivity to the iodine therapy.
WARNING: Large doseage may cause iodine poisoning.
FEDERAL LAW PROHIBITS DISPENSING WITHOUT A PRESCRIPTION.
In case of acciedntal overose, seek professional assistance or contact a Poison Control Center immediately.
VESICATION AND DESQUAMATION MAY OCCUR IF ALLOWED TO POOL IN CONTACT WITH THE SKIN. EXCESS IODINE SHOULD BE REMOVED WITH ALCOHOL TO PREVENT "IODINE BURNS."
Iodine therapy does not completly control the manifestations of hyperthyroidism in that after a variable period of time, the beneficial effects wear off. With continue administration of iodine, the hyperthyroidism may return in its initial intensity or may become even more severe than it was at first. Measurements of the protein bound iodine or of the uptake of radioiodine are rendered useless if iodine is given. Average dosage of iodine may cause skin rash. Iodine readily crosses the placental barrier and may affect the fetus. Prolonged therapy may cause iodism. The ingestion of large quantities of iodine may casue abdominal pain, nausea, vomiting and diarhea.
If in eyes: Immediately flush eyes with plenty of water for 15 minutes.
If on skin: Immediately wash skin with plenty of water for 15 minutes.
If swallowed: CALL A PHYSICIAN. Do not induce vomiting. If conscious, give water, milk, or milk of magnesia.
DOSAGE: USUAL DOSE; 4-1/2 minimis 3 times daily. Dilute with water or juie.
USUSAL DOSE RANGE: 1-1/2 to 15 minims daily.
CAUTION: THIS CONTAINER IS NOT "CHILD PROOF" AND MUST NOT BE SOLD FOR USE IN OR AROUND THE HOME.
Purified water
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0395-2775-16 | ML - Milliliter | 0395-2775 | 3737363e-5d60-4b66-a9b6-fe93bd041165 | 1 | 2013-11-04 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| IODINE | ACTIVE INGREDIENT | 9679TC07X4 | 2 | |
| POTASSIUM IODIDE | ACTIVE INGREDIENT | 1C4QK22F9J | 2 | |
| IODIDE ION | ACTIVE MOIETY | 09G4I6V86Q | 2 | |
| IODINE | ACTIVE MOIETY | 9679TC07X4 | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0395-2775 | 0395-2775-16 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| WATER | 059QF0KO0R | IACT |
| IODINE | 9679TC07X4 | ACTIB |
| POTASSIUM IODIDE | 1C4QK22F9J | ACTIM |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| da6c5009-ea01-25c6-e053-2995a90ab727 | cf5b0102-4f76-4f9e-907a-bf9425890aea | 2022-03-17 | Warnings | da6c5009-ea01-25c6-e053-2995a90ab727 cf5b0102-4f76-4f9e-907a-bf9425890aea |
Adverse event summaries are temporarily unavailable. Other product information remains available.